• Inotersen NDA Accepted for Priority Review by FDA americanpharmaceuticalreview
    January 09, 2018
    Ionis Pharmaceuticals announced its New Drug Application (NDA) for inotersen has been accepted for Priority Review by the U.S. Food and Drug Administration (FDA)
PharmaSources Customer Service